首页/数据集/Tasquinimod, a Quinoline-3-Carboxamide Anti-Angiogenic Agent, treated Prostate Cancer Cell Line in-vivo and in-vitro

Tasquinimod, a Quinoline-3-Carboxamide Anti-Angiogenic Agent, treated Prostate Cancer Cell Line in-vivo and in-vitro

ChEBI2011-03-01 更新2026-07-21 收录

前列腺癌靶向治疗

抗血管生成药物

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-17031 数据链接链接失效反馈

官方服务：

资源简介：

Tasquinimod, a Quinoline-3-Carboxamide Anti-Angiogenic Agent, treated Prostate Cancer Cell Line in-vivo and in-vitro

应用场景：

创建时间：

2011-03-01

前列腺癌靶向治疗

上皮-间质转化抑制

Castration Resistant Prostate Cancer (CRPC) is thought to be driven by a collaborative mechanism between TNFα/NFκB and TGFβ signaling, leading to inflammation, Epithelial-to-Mesenchymal-Transition (EM

NIAID Data Ecosystem50

Targeting the N-terminus of the androgen receptor for prostate cancer therapy

前列腺癌靶向治疗

雄激素受体抑制剂

All current clinically approved androgen deprivation therapies for prostate cancer (PCa) target the C-terminal ligand-binding domain (LBD) of the androgen receptor (AR), although the N-terminal domain

NIAID Data Ecosystem20

Modulation of growth and angiogenesis of OSCC cells with Sal B. Homo sapiens

口腔癌研究

抗血管生成药物

In this study we used in vitro approaches to investigate whether it has any inhibitory properties on OSCC cells. We also tried to understand the possible mechanisms of Sal B on this type of malignancy

NIAID Data Ecosystem10

Discovery of Potent DYRK2 Inhibitors with High Selectivity, Great Solubility, and Excellent Safety Properties for the Treatment of Prostate Cancer

DYRK2

前列腺癌靶向治疗

Prostate cancer (PCa) is a common male cancer with high incidence and mortality, and hormonal therapy as the major treatment for PCa patients is troubled by the inevitable resistance that makes us ide

NIAID Data Ecosystem30

Dataset from A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)

非小细胞肺癌治疗

抗血管生成药物

This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung can

NIAID Data Ecosystem10

Tasquinimod, a Quinoline-3-Carboxamide Anti-Angiogenic Agent, treated Prostate Cancer Cell Line in-vivo and in-vitro

资源简介：

相关数据集